- Home
- OLP vs EYPT Comparison
OLP vs EYPT Comparison
Compare OLP & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLP | EYPT |
|---|---|---|
| Founded | 1982 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.4M | 1.1B |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | OLP | EYPT |
|---|---|---|
| Price | $22.12 | $13.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $27.50 | ★ $31.80 |
| AVG Volume (30 Days) | 78.3K | ★ 939.2K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 8.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $82,740,000.00 | $7,539,000.00 |
| Revenue This Year | $11.98 | N/A |
| Revenue Next Year | $3.71 | $1,031.72 |
| P/E Ratio | $19.15 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $19.62 | $3.91 |
| 52 Week High | $25.90 | $19.11 |
Technical Indicators
Market Signals| Indicator | OLP | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 44.07 |
| Support Level | $21.94 | $12.47 |
| Resistance Level | $22.30 | $13.32 |
| Average True Range (ATR) | 0.51 | 0.72 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 38.74 | 55.70 |
Price Performance
Historical ComparisonAbout OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.